Clinical Trials Logo

Filter by:
NCT ID: NCT05338567 Recruiting - Clinical trials for Small Intestine Length Measurement

Digital 3D Reconstruction Predicts Small Bowel Length

DTDRPSBL-BS
Start date: October 2, 2019
Phase:
Study type: Observational

The prevalence of type 2 diabetes mellitus (T2DM) has been increasing annually worldwide, and the prevalence of diabetes has reached 11.6% in China. Laparoscopic Roux-en-Y gastric bypass (RYGB) is still widely accepted as a valid surgery in the treatment of obesity and T2DM. But still, there is no consensus on the ideal of the gastric bypass limb lengths. Reported lengths of biliopancreatic limb (BPL) and alimentary limb (AL) varied widely from 10-250 to 35-250 cm, and anatomical data show that the length of small intestine varies greatly among adults. Choosing the same small bowel bypass length for different individuals obviously cannot achieve the expected weight loss effect, and individuals with too short small intestine can cause severe malnutrition complications and even life-threatening conditions. Therefore, measurement of small bowel length is one of the prerequisites for performing precise RYGB. Intraoperative measurement of small bowel length can increase the operative time and the risk of surgical complications such as intestinal perforation. So, predicting the total length of the small intestine is very important for accurately performing bariatric surgery and avoiding the risk of surgical complications. In this study, we propose to perform 3D segmentation and reconstruction of the small intestine by acquiring abdominal CT data through digital technology, and predict the small intestine length by 3D digital measurement of the small intestine, and verify the digital measurement data by performing digital measurement data. Establish a small bowel length prediction model for bariatric surgery to develop a more accurate and personalized gastric bypass surgery plan for patients to obtain weight loss and glucose control.

NCT ID: NCT05338541 Recruiting - Clinical trials for Neuroblastoma in Children

Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.

CSIIT-Q36
Start date: May 27, 2022
Phase: Phase 1
Study type: Interventional

Neuroblastoma is a malignant tumor that develops in infants and kids. Dysregulation of histone acetylation is associated with a series of malignant tumors. Neuroblastoma is caused by defective neural crest differentiation due to abnormal gene regulation.

NCT ID: NCT05338294 Recruiting - Cirrhosis, Liver Clinical Trials

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on the Immune Function for Cirrhosis Patients

ELSDI
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

In this study, the investigators compared the improvement of immune function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection. To determine whether surgical treatment can help enhance postoperative immune function and improve patient prognosis.

NCT ID: NCT05337657 Recruiting - Clinical trials for Advanced Breast Cancer

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Start date: June 2, 2021
Phase: Phase 1
Study type: Interventional

GB491-005 is a multicenter, open-label, phase Ib Clinical Trial study to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GB491 in combination with Letrozole in Previously Untreated Patients with HR-positive, HER2-negative Advanced Breast Cancer

NCT ID: NCT05337319 Recruiting - Clinical trials for Coronary Artery Disease

Prospective Registry of the Current Status of Care for Patients With Coronary Artery Disease

Start date: January 17, 2022
Phase:
Study type: Observational

The study will estimate the current status of care for participants with coronary artery disease

NCT ID: NCT05337189 Recruiting - Bladder Cancer Clinical Trials

A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China

Start date: March 9, 2022
Phase:
Study type: Observational

The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose bladder cancer by comparing with clinical standard method (includes medical imaging (MRI, CT, etc.), cystoscopy, pathological examination).

NCT ID: NCT05337137 Recruiting - Clinical trials for Carcinoma, Hepatocellular

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

RELATIVITY-106
Start date: May 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).

NCT ID: NCT05336851 Recruiting - Sepsis Clinical Trials

Emergency PWAS in Respiratory Infectious Disease

Start date: April 11, 2023
Phase:
Study type: Observational [Patient Registry]

Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID). Phase 1 1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2 2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics

NCT ID: NCT05336799 Recruiting - Myopia Clinical Trials

Prevalence and Environmental Factors for Myopia Among Chinese School-aged Children and Adolescent in Tianjin

Start date: March 1, 2021
Phase:
Study type: Observational

The high prevalence of myopia has become a global public health problem. The study amied to investigate the prevalence and progression of myopia associated with social environmental factors in Tianjin, a Chinese megacity in north China.

NCT ID: NCT05336721 Recruiting - Clinical trials for Triple-negative Breast Cancer

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Start date: November 5, 2021
Phase: Phase 2
Study type: Interventional

This study is to evaluate the preliminary efficacy and safety of chiauranib in combine with capecitabine in advanced triple-negative breast cancer failed to prior anthracyclines and taxanes therapy